Welcome to our dedicated page for Verve Therapeutics news (Ticker: VERV), a resource for investors and traders seeking the latest updates and insights on Verve Therapeutics stock.
This page provides a historical news archive for Verve Therapeutics, Inc. (former Nasdaq: VERV), a clinical-stage company that has focused on developing genetic medicines for cardiovascular disease. News coverage about Verve highlights its work on in vivo base editing and single-course gene editing medicines intended to permanently turn off genes in the liver that drive atherosclerotic cardiovascular disease and high-risk lipid disorders.
Articles in this feed describe Verve’s lead programs – VERVE-102, VERVE-201, and VERVE-301 – which target PCSK9, ANGPTL3, and LPA, respectively. News items detail clinical trial progress for VERVE-102 in the Heart-2 Phase 1b study in adults with heterozygous familial hypercholesterolemia and premature coronary artery disease, including reported dose-dependent reductions in LDL-C and PCSK9 protein levels and safety observations from early cohorts. Other updates cover the Pulse-1 Phase 1b trial of VERVE-201 in refractory hypercholesterolemia and homozygous familial hypercholesterolemia, as well as preclinical and collaboration milestones for VERVE-301 aimed at lowering lipoprotein(a).
In addition to clinical and regulatory updates, the news stream includes announcements about U.S. FDA Fast Track designation for VERVE-102, investigational new drug clearance, equity inducement grants, investor conference participation, and quarterly pipeline summaries. A significant portion of the coverage also relates to Eli Lilly and Company’s agreement to acquire Verve, the tender offer for Verve’s common stock, and the completion of the merger that resulted in Verve becoming an indirect wholly-owned subsidiary of Eli Lilly.
Because Verve’s common stock has been delisted from Nasdaq and the company has suspended its SEC reporting obligations, this page functions as a historical record of VERV-related news, useful for investors and researchers analyzing the development of single-course gene editing approaches in cardiovascular disease and the corporate events leading to Verve’s acquisition.
Verve Therapeutics has granted equity awards to six new employees as inducement for employment. The awards include 47,600 stock options with an exercise price of $5.73 per share and 42,710 restricted stock units (RSUs). The options have a 10-year term, vesting over four years with 25% vesting after one year and the remainder monthly over three years. The RSUs will vest in equal annual installments over four years starting January 1, 2025. These grants were made under the company's 2024 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Verve Therapeutics, a clinical-stage company developing genetic medicines for cardiovascular disease, has announced the granting of equity awards to five new employees on September 30, 2024. These awards, made under the company's 2024 Inducement Stock Incentive Plan, are in accordance with Nasdaq Listing Rule 5635(c)(4) and serve as an inducement for employment.
The equity awards consist of an aggregate of 33,280 restricted stock units (RSUs). These RSUs will vest in equal annual installments over four years, starting from October 1, 2024, contingent on the employees' continued service with Verve Therapeutics.
Verve Therapeutics, a clinical-stage company focused on developing genetic medicines for cardiovascular disease, has announced the granting of equity awards to two new employees. The awards, issued on August 30, 2024, consist of a total of 12,600 restricted stock units (RSUs). These grants were made under the company's 2024 Inducement Stock Incentive Plan and are in compliance with Nasdaq Listing Rule 5635(c)(4).
The RSUs will vest in equal annual installments over a four-year period, starting from October 1, 2024, contingent on the employees' continued service with Verve Therapeutics. This move is part of the company's strategy to attract and retain talent in the competitive biotech sector.
Verve Therapeutics, a clinical-stage company developing genetic medicines for cardiovascular disease, reported Q2 2024 financial results and pipeline updates. Key highlights include:
- Heart-2 clinical trial of VERVE-102 enrolling in the U.K., Canada, and Australia
- VERVE-201 Phase 1b trial initiation on track for H2 2024
- Cash position of $575.9 million, runway into late 2026
- Q2 2024 revenue: $6.7 million; net loss: $49.8 million ($0.59 per share)
- R&D expenses: $51.0 million; G&A expenses: $14.5 million
The company plans to provide initial data from the Heart-2 trial and a PCSK9 program update in H1 2025, with Phase 2 trial initiation expected in H2 2025.
Verve Therapeutics, a clinical-stage company developing genetic medicines for cardiovascular disease, has announced the granting of equity awards to five new employees on July 31, 2024. These awards, made under the company's 2024 Inducement Stock Incentive Plan, include:
1. Stock options to purchase 91,200 shares of common stock at $7.00 per share, vesting over four years.
2. 37,300 restricted stock units (RSUs), vesting in equal annual installments over four years.
These grants are in accordance with Nasdaq Listing Rule 5635(c)(4) and are designed to serve as an inducement for new employees joining the company.
Verve Therapeutics, a clinical-stage biotech firm, announced the granting of equity awards to a new employee under its 2024 Inducement Stock Incentive Plan, as per Nasdaq Listing Rule 5635(c)(4). On June 28, 2024, the new hire received a stock option to purchase 76,900 shares at an exercise price of $4.88 per share, the closing price on the grant date. The option has a 10-year term, with 25% vesting on the first anniversary and the remainder vesting monthly over three years. Additionally, 19,200 restricted stock units (RSUs) were granted, set to vest in equal annual installments over four years from July 1, 2024, contingent on continued service.
Verve Therapeutics, a clinical-stage biotechnology company specializing in gene editing medicines for cardiovascular diseases, announced the appointment of Dr. Nia Tatsis and Jodie Morrison to its Board of Directors. Dr. Tatsis is the EVP, Chief Regulatory and Quality Officer at Vertex Pharmaceuticals, boasting extensive experience in regulatory affairs and quality control. Jodie Morrison, CEO of Q32 Bio, brings two decades of leadership in biopharmaceuticals, including successful mergers and IPOs. Their expertise will support Verve's ongoing clinical trials, including the Heart-2 trial for VERVE-102 targeting the PCSK9 gene and the initiation of the VERVE-201 trial targeting the ANGPTL3 gene.
On May 31, 2024, Verve Therapeutics, a clinical-stage biotech firm focusing on gene editing medicines for cardiovascular disease, announced the granting of equity awards to four new employees under its 2024 Inducement Stock Incentive Plan. Following Nasdaq Listing Rule 5635(c)(4), the employees received a combined total of 23,600 restricted stock units (RSUs). These RSUs will vest annually over four years starting from July 1, 2024, contingent upon continued employment.
Verve Therapeutics has announced a leadership update with Troy Lister, Ph.D., being promoted to Chief Scientific Officer (CSO), effective June 21, 2024. Lister has been with Verve for two years, bringing over 15 years of experience, including roles at Spero Therapeutics, Novartis, and AstraZeneca.
Andrew Bellinger, M.D., Ph.D., the outgoing CSO who has served since 2019, will continue in an advisory capacity. Bellinger significantly contributed to Verve's pipeline development and preclinical and clinical programs.
CEO Sekar Kathiresan, M.D., praised both Lister and Bellinger for their contributions and leadership in advancing Verve's mission to develop gene-editing medicines for cardiovascular disease.
Verve Therapeutics, a clinical-stage biotechnology company specializing in gene editing for cardiovascular disease, announced its participation in two upcoming investor conferences. Management will engage in fireside chats at the Jefferies Global Healthcare Conference on June 6, 2024, at 1 p.m. ET in New York, NY, and the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024, at 8 a.m. ET in Miami Beach, FL. Live webcasts of these events will be available on the company's website and will remain accessible for 30 days post-event.